SINOPHARM(01099): Net profit attributable to the parent company in 2025 was 19.97 billion yuan, a year-on-year decrease of 0.18% for China National Medicines Corporation (600511.SH).

SINOPHARM (01099) has announced China National Medicines Corporation's (600511.SH) performance for the year 2025, achieving operating income of 52.468 billion yuan, a year-on-year increase of 3.70%; total profit of 2.6 billion yuan, a year-on-year decrease of 2.01%; net profit of 2.089 billion yuan, a year-on-year decrease of 1.90%; net profit attributable to the parent company of 1.997 billion yuan, a year-on-year decrease of 0.18%; non-recurring net profit attributable to the parent company of 1.971 billion yuan, a year-on-year decrease of 1.28%; and net cash flow from operating activities reaching 2.006 billion yuan. As of December 31, 2025, total assets were 36.685 billion yuan, owner's equity attributable to shareholders of the listed company was 18.545 billion yuan, and the return on net assets (weighted) was 11.26%.